A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 884 participants.

Also called NCT01191268

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 884 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01191268
Other papers using this trial's data
  • Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study Lancet (London, England), 2015-05-23 DOI, PubMed 26009229

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Greece, Hungary, Mexico, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01191268. Randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2014-10-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
LY2189265
Intervention (Drug)
Insulin Lispro
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01191268
Content hash
eb0f390fa16fe3b5721f22d11979b97b36e4749c6174fa268224ee5fe593081f